Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies
Genes · 24.12.2024 · 16 (1) · 6
DOI: 10.3390/genes16010006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 24.12.2024. Verfasst von Giandomenico Roviello und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science, University of Florence, 50134 Florence, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mutations of the von Hippel–Lindau (VHL) tumor suppressor gene occur frequently in clear cell renal cell carcinoma (RCC), the predominant histology of kidney cancer, and have been associated with its pathogenesis and progression. Alterations of VHL lead to impaired degradation of hypoxia-inducible factor 1α (HIF1α) and HIF2α promoting neoangiogenesis, which is pivotal for cancer growth. As such, targeting the VHL-HIF axis holds relevant potential for therapeutic purposes. Belzutifan, an HIF-2α inhibitor, has been recently indicated for metastatic RCC and other antiangiogenic drugs directed against HIF-2α are currently under investigation. Further, clinical and preclinical studies of combination approaches for metastatic RCC including belzutifan with cyclin-dependent kinase 4–6 inhibitors, tyrosine kinase inhibitors, or immune checkpoint inhibitors achieved promising results or are ongoing. This review aims to summarize the existing evidence regarding the VHL/HIF pathway, and the approved and emerging treatment strategies that target this pivotal molecular axis and their mechanisms of resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Science, University of Florence, 50134 Florence, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
- Department of Medicine, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield S10 2JF, UK.
- Clinical Oncology Unit, Careggi University Hospital, 50234 Florence, Italy.
- Department of Health Sciences, Section of Anatomic Pathology, University of Florence, 50139 Florence, Italy.
ORCID-Profile: Giandomenico Roviello, Alberto D'Angelo, Edoardo Francini, Roberta Giorgione, Gabriella Nesi, Martina Catalano
Zitieren
APA
Roviello, G., De Gennaro, I., Vascotto, I., Venturi, G., D'Angelo, A., Winchler, C., Guarino, A., Cacioppo, S., Modesti, M., Mela, M. M., Francini, E., Doni, L., Rossi, V., Gambale, E., Giorgione, R., Antonuzzo, L., Nesi, G., & Catalano, M. (2024). Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies. Genes, 16(1), 6. https://doi.org/10.3390/genes16010006
Vancouver
Roviello G, De Gennaro I, Vascotto I, Venturi G, D'Angelo A, Winchler C, et al. Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies. Genes. 2024;16(1):6. doi:10.3390/genes16010006
BibTeX
@article{Roviello2024,
author = {Roviello, Giandomenico and De Gennaro, Irene and Vascotto, Ismaela and Venturi, Giulia and D'Angelo, Alberto and Winchler, Costanza and Guarino, Adriana and Cacioppo, Salvatore and Modesti, Mikol and Mela, Marinella Micol and Francini, Edoardo and Doni, Laura and Rossi, Virginia and Gambale, Elisabetta and Giorgione, Roberta and Antonuzzo, Lorenzo and Nesi, Gabriella and Catalano, Martina},
title = {Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies},
journal = {Genes},
year = {2024},
volume = {16},
number = {1},
pages = {6},
doi = {10.3390/genes16010006}
}
EUVIMED